We found similar outcomes in this study, the amplification rate of FGFR1 in the TCGA dataset was up to 13%, and the median months overall of the FGFR1 altered BC patients was 127.33, shorter than the unaltered group. The gene discussed is FGFR1; the disease is breast cancer.